Castle Biosciences (CSTL) Total Debt (2018 - 2026)

Castle Biosciences (CSTL) has 7 years of Total Debt data on file, last reported at $10.1 million in Q1 2026.

• Quarterly Total Debt changed 0.34% year-over-year to $10.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.1 million (changed 0.34% YoY) and the FY2025 annual result came in at $10.1 million, changed 0.34% from the prior year.
• Total Debt steadied at $10.1 million in Q1 2026 per CSTL's latest filing, from $10.1 million in the prior quarter.
• The five-year high for Total Debt was $20.8 million in Q1 2022, with the low at $10.0 million in Q1 2024.
• Average Total Debt over 4 years is $11.1 million, with a median of $10.0 million recorded in 2025.
• The widest YoY moves for Total Debt: up 0.34% in 2025, down 0.32% in 2025.
• Castle Biosciences' Total Debt stood at $20.8 million in 2022, then tumbled by 51.93% to $10.0 million in 2024, then grew by 0.34% to $10.1 million in 2025, then increased by 0.09% to $10.1 million in 2026.
• Business Quant data shows CSTL's Total Debt at $10.1 million in Q1 2026, $10.1 million in Q4 2025, and $10.0 million in Q3 2025.